Jul 2 |
Neurogene to Participate in BMO Genetic Medicines Summit
|
Jul 1 |
Neurogene to join Russell 3000 Index
|
Jul 1 |
Neurogene Announces Addition to Russell 3000® Index
|
Jun 18 |
Neurogene Announces First Patient Dosed in High-Dose Cohort of NGN-401 Gene Therapy Clinical Trial for Rett Syndrome
|
Jun 11 |
Neurogene a new outperform at Baird on gene therapy for Rett syndrome
|
Jun 5 |
Neurogene to Participate in Upcoming Conferences
|
Jun 3 |
Neurogene Announces NGN-401 Gene Therapy for Rett Syndrome Selected by FDA for START Pilot Program
|
May 10 |
Neurogene GAAP EPS of -$1.00 beats by $0.03
|
May 10 |
Neurogene Reports First Quarter 2024 Financial Results and Highlights Recent Updates
|
May 7 |
Neurogene Presents Favorable Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome during ASGCT Annual Meeting
|